Want to join the conversation?
$LGND said it signed a license agreement with Tizona Therapeutics to provide its OmniRat, OmniMouse & OmniFlic platforms to generate fully human mono- and bispecific antibodies. Ligand will be eligible to receive platform access payments as well as patent filing fees, clinical milestone payments and royalties for each successful OmniAb antibody.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.